AstraZeneca's oral GLP-1 drug elecoglipron met primary endpoints in two Phase 2 trials:
VISTA (weight loss in 310 obesity/overweight patients over 26-36 weeks) and SOLSTICE (blood sugar control in 406 Type 2 diabetes patients vs. placebo/semaglutide). 1234
The company is advancing elecoglipron into Phase 3 development in 2026, but full data will be disclosed at the American Diabetes Association conference in June 2026. 123
CEO Pascal Soriot described elecoglipron as having a 'very competitive profile,' justifying the Phase 3 investment. 13
No specific mention of key cancer trials being pushed back in recent announcements; focus is on positive obesity results and portfolio growth including AZD6234 and CSPC deal. 13
Sources:
1. https://www.fiercebiotech.com/biotech/astrazeneca-reveals-oral-glp1-scored-phase-2-wins-holds-back-weight-loss-data
2. https://www.techtarget.com/pharmalifesciences/news/366638995/AstraZenecas-GLP-1-pill-succeeds-in-two-mid-stage-trials
3. http://business.times-online.com/times-online/article/marketminute-2026-2-10-astrazeneca-signals-a-new-era-in-obesity-care-earnings-report-teases-oral-glp-1-powerhouse
4. https://www.biospace.com/business/astrazeneca-teases-very-competitive-weight-loss-pill-but-stays-mum-on-details